Loading...
Loading...
Browse all stories on DeepNewz
VisitWhich type of disease will be most impacted by Brodin's study findings by September 30, 2025?
Autoimmune diseases • 25%
Infectious diseases • 25%
Cancer • 25%
Other • 25%
Scientific literature and peer-reviewed articles
Nature Study by Petter Brodin Finds Testosterone Therapy Alters Immune System in Trans Men
Sep 4, 2024, 03:24 PM
Recent research published in Nature reveals that gender-affirming testosterone therapy in trans men results in significant changes to their immune systems, making them more similar to cisgender men. The study, led by Petter Brodin and colleagues, highlights that testosterone therapy reduces type I interferon and enhances TNF signatures. This research provides insights into why males are more vulnerable to severe infections, such as acute COVID-19, while females are more prone to autoimmune diseases like SLE and MS. The findings, published in Nature, could help scientists better understand sex differences in immune responses among both cisgender and transgender individuals.
View original story
Cardiovascular disease • 25%
Diabetes • 25%
Cancer • 25%
Other • 25%
Obesity • 25%
Cardiovascular disease • 25%
Mental health disorders • 25%
Cancer • 25%
Cancer • 33%
Neurodegenerative diseases • 33%
Cardiovascular diseases • 33%
Cancer • 25%
Neurodegenerative diseases • 25%
Cardiovascular diseases • 25%
Other • 25%
Diabetes • 25%
Cancer • 25%
Cardiovascular diseases • 25%
Other • 25%
Cancer • 25%
Cardiovascular Diseases • 25%
Neurodegenerative Diseases • 25%
Other • 25%
Persistent viral RNA • 25%
T cell activation • 25%
Chronic inflammation • 25%
Other • 25%
0-10 • 25%
11-50 • 25%
51-100 • 25%
101+ • 25%
Immune response • 25%
Viral persistence • 25%
Organ damage • 25%
Other • 25%
Cancer treatment • 25%
Neurodegenerative diseases • 25%
Infectious diseases • 25%
Cardiovascular diseases • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Sex differences in disease susceptibility • 25%
Gender-affirming therapies • 25%
Other • 25%
Immune response studies • 25%